Valuation: Cytokinetics, Incorporated

Capitalization 821.62Cr 697.23Cr 639.06Cr 606.88Cr 1.12TCr 76TCr 1.15TCr 7.5TCr 2.95TCr 37TCr 3.08TCr 3.02TCr 1,30300Cr P/E ratio 2026 *
-10.3x
P/E ratio 2027 * -13.9x
Enterprise value 802.53Cr 681.03Cr 624.21Cr 592.78Cr 1.1TCr 75TCr 1.12TCr 7.32TCr 2.88TCr 36TCr 3.01TCr 2.95TCr 1,27300Cr EV / Sales 2026 *
86.4x
EV / Sales 2027 * 20.8x
Free-Float
98.67%
Yield 2026 *
-
Yield 2027 * -
1 day-0.58%
1 week-0.82%
Current month+0.39%
1 month+7.24%
3 months+3.75%
6 months+11.49%
Current year+4.14%
1 week 63.97
Extreme 63.97
67.52
1 month 59.03
Extreme 59.03
68.71
Current year 58.43
Extreme 58.43
70.39
1 year 29.31
Extreme 29.31
70.98
3 years 25.98
Extreme 25.98
110.25
5 years 17.72
Extreme 17.72
110.25
10 years 5.75
Extreme 5.75
110.25
Manager TitleAgeSince
Chief Executive Officer 62 01/01/2007
Director of Finance/CFO 56 08/05/2024
Chief Administrative Officer 57 14/11/2025
Director TitleAgeSince
Director/Board Member 62 01/01/2007
Chairman 81 08/04/2022
Director/Board Member 78 09/02/2011
Change 5d. change 1-year change 3-years change Capi.($)
-0.57%-0.82%+74.45%+80.84% 821.62Cr
-1.42%+4.52%+35.30%+104.04% 5.27TCr
+0.37%-6.18%+88.76%+25.71% 4.41TCr
-0.74%-5.04%+106.49%+710.90% 3.12TCr
+1.78%+8.60%+3.15%-13.16% 2.6TCr
+0.52%+25.86%-0.04%+1,485.53% 1.95TCr
-0.39%-0.89%+73.56%-33.56% 1.89TCr
-2.72%+6.30%+77.09%+229.37% 1.78TCr
-1.61%-1.14%+36.75%-36.15% 1.75TCr
-2.69%+2.64%+77.30% - 1.55TCr
Average -0.76%+4.55%+57.28%+283.72% 2.51TCr
Weighted average by Cap. -0.62%+3.22%+57.23%+258.17%

Financials

2026 *2027 *
Net sales 9.29Cr 7.88Cr 7.23Cr 6.86Cr 13Cr 863.94Cr 13Cr 85Cr 33Cr 416.83Cr 35Cr 34Cr 1.47TCr 38Cr 32Cr 29Cr 28Cr 51Cr 3.49TCr 52Cr 342.59Cr 134.74Cr 1.68TCr 140.83Cr 137.9Cr 5.95TCr
Net income -82Cr -70Cr -64Cr -61Cr -112.39Cr -7.66TCr -114.79Cr -751.29Cr -295.48Cr -3.69TCr -308.83Cr -302.42Cr -13TCr -64Cr -55Cr -50Cr -48Cr -88Cr -6TCr -90Cr -588.53Cr -231.47Cr -2.89TCr -241.93Cr -236.91Cr -10TCr
Net Debt -19Cr -16Cr -15Cr -14Cr -26Cr -1.78TCr -27Cr -174.16Cr -68Cr -856.44Cr -72Cr -70Cr -3.03TCr -42Cr -36Cr -33Cr -31Cr -58Cr -3.92TCr -59Cr -384.44Cr -151.2Cr -1.89TCr -158.03Cr -154.75Cr -6.68TCr
Logo Cytokinetics, Incorporated
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
Employees
673
Date Price Change Volume
21/26/21 66.14 $ -0.85% 5,28,708
17/26/17 66.71 $ +1.97% 14,99,226
16/26/16 65.42 $ +0.08% 11,68,813
15/26/15 65.37 $ -1.48% 12,59,908
14/26/14 66.35 $ -0.55% 18,97,144
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
66.71USD
Average target price
92.94USD
Spread / Average Target
+39.33%

Quarterly revenue - Rate of surprise